Loading
Journal of Clinical Haematology
ISSN: 2766-4686
Treatment of Traumatic Brain Injury: Nanotherapeutics
Nanotechnology and regenerative nanotherapeutics enrich the renewing features and function of the diseased cells and tissue by replenishing the local environment, while inhibiting further degeneration. These featured therapeutics perform cell maintenance and promote cellular events to develop better communication between re-forming molecules of remedies and the brain.
J Clin Haematol, 2024, Volume 5, Issue 1, p1-3 | DOI: 10.33696/haematology.5.056Voting Engagement among Adults with Sickle Cell Disease (SCD): Health Matters
The Voting Rights Act of 1965 was established to enforce voting rights guaranteed by the Fourteenth and Fifteenth amendments. Unfortunately, Blacks faced additional barriers when attempting to exercise their right to vote. Moreover, focusing on voting specifically among adults living with Sickle Cell Disease (SCD), we assessed voter participation as a form of advocacy to evaluate if political involvement was related to psychological status.
J Clin Haematol, 2024, Volume 5, Issue 1, p4-11 | DOI: 10.33696/haematology.5.057Toward Precision Medicine for Patients with Multiple Myeloma
Multiple myeloma (MM), the second most common hematologic malignancy, is a plasma cell neoplasm that arises from a precursor, monoclonal gammopathy of undetermined significance (MGUS), which may or may not be previously diagnosed. Smoldering multiple myeloma (SMM), another precursor of MM, lacks myeloma-defining events and end-organ damage that are diagnostic of MM in the appropriate clinical settings. Newly diagnosed MM (NDMM) is highly heterogeneous genetically and clinically with very variable survival outcomes ranging from a few months to over a decade.
J Clin Haematol, 2024, Volume 5, Issue 1, p12-33 | DOI: 10.33696/haematology.5.058Decoding Hodgkin's Lymphoma: Advances in Biology, Diagnostics, and Therapeutic Strategies
Background: Hodgkin's lymphoma (HL) is a malignancy of the lymphatic system characterized by Reed-Sternberg cells. While current treatments have improved outcomes, challenges remain in managing relapsed/refractory disease and mitigating long-term toxicities. Purpose: This review aims to summarize recent advances in HL biology, diagnostics, and treatment strategies, with a focus on novel therapeutic approaches and emerging research areas.
J Clin Haematol, 2024, Volume 5, Issue 1, p34-46 | DOI: 10.33696/haematology.5.059Scientific Archives is a global publisher initiated with the mission of ensuring equal opportunity for accessing science to research community all over the world. Spreading research findings with great relevance to all channels without any barrier is our goal. We want to overcome the challenges of Open Access with ensured quality and transparency.